Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 25

1.

Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model.

Wernig G, Mercher T, Okabe R, Levine RL, Lee BH, Gilliland DG.

Blood. 2006 Jun 1;107(11):4274-81. Epub 2006 Feb 14.

2.

Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).

Michiels JJ, Bernema Z, Van Bockstaele D, De Raeve H, Schroyens W.

Pathol Biol (Paris). 2007 Mar;55(2):92-104. Epub 2006 Aug 21. Review.

PMID:
16919893
4.

Polycythemia vera: scientific advances and current practice.

Tefferi A, Spivak JL.

Semin Hematol. 2005 Oct;42(4):206-20. Review.

PMID:
16210034
5.

Diagnosis, pathogenesis and treatment of the myeloproliferative disorders essential thrombocythemia, polycythemia vera and essential megakaryocytic granulocytic metaplasia and myelofibrosis.

Michiels JJ, Kutti J, Stark P, Bazzan M, Gugliotta L, Marchioli R, Griesshammer M, van Genderen PJ, Brière J, Kiladjian JJ, Barbui T, Finazzi G, Berlin NI, Pearson TC, Green AC, Fruchtmann SM, Silver RT, Hansmann E, Wehmeier A, Lengfelder E, Landolfi R, Kvasnicka HM, Hasselbalch H, Cervantes F, Thiele J, et al.

Neth J Med. 1999 Feb;54(2):46-62. Review.

PMID:
10079679
6.

The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders.

Michiels JJ, De Raeve H, Berneman Z, Van Bockstaele D, Hebeda K, Lam K, Schroyens W.

Semin Thromb Hemost. 2006 Jun;32(4 Pt 2):307-40. Review.

PMID:
16810609
7.

Role of tyrosine kinases and phosphatases in polycythemia vera.

Zhao ZJ, Vainchenker W, Krantz SB, Casadevall N, Constantinescu SN.

Semin Hematol. 2005 Oct;42(4):221-9. Review.

PMID:
16210035
8.

Polycythemia vera: new clinicopathologic perspectives.

Cao M, Olsen RJ, Zu Y.

Arch Pathol Lab Med. 2006 Aug;130(8):1126-32. Review.

PMID:
16879013
9.

[Acquired mutation of JAK2 tyrosine kinase and polycythaemia vera].

Pargade V, Darnige L, Gaussem P.

Ann Biol Clin (Paris). 2006 Jan-Feb;64(1):3-9. Review. French.

10.

Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.

Michiels JJ, Berneman Z, Schroyens W, De Raeve H.

Acta Haematol. 2015;133(1):36-51. doi: 10.1159/000358580. Epub 2014 Aug 7. Review.

PMID:
25116092
11.

Essential thrombocythemia vs. early/prefibrotic myelofibrosis: why does it matter.

Barosi G.

Best Pract Res Clin Haematol. 2014 Jun;27(2):129-40. doi: 10.1016/j.beha.2014.07.004. Epub 2014 Jul 18. Review.

PMID:
25189724
12.

Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management.

Tefferi A, Barbui T.

Am J Hematol. 2015 Feb;90(2):162-73. doi: 10.1002/ajh.23895. Review. Erratum in: Am J Hematol. 2015 Sep;90(9):849.

13.

Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications.

Michiels JJ, Berneman Z, Van Bockstaele D, van der Planken M, De Raeve H, Schroyens W.

Semin Thromb Hemost. 2006 Apr;32(3):174-207. Review.

PMID:
16673274
14.

Polycythemia vera and its molecular basis: an update.

Chen G, Prchal JT.

Best Pract Res Clin Haematol. 2006;19(3):387-97. Review.

PMID:
16781479
15.

Chronic idiopathic myelofibrosis: clinicopathologic features, pathogenesis, and prognosis.

Ahmed A, Chang CC.

Arch Pathol Lab Med. 2006 Aug;130(8):1133-43. Review.

PMID:
16879014
16.

JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science.

Kilpivaara O, Levine RL.

Leukemia. 2008 Oct;22(10):1813-7. doi: 10.1038/leu.2008.229. Epub 2008 Aug 28. Review.

PMID:
18754026
17.

Narrative review: Thrombocytosis, polycythemia vera, and JAK2 mutations: The phenotypic mimicry of chronic myeloproliferation.

Spivak JL.

Ann Intern Med. 2010 Mar 2;152(5):300-6. doi: 10.7326/0003-4819-152-5-201003020-00008. Review.

PMID:
20194236
18.

Physiopathology, etiologic factors, diagnosis, and course of polycythemia vera as related to therapy according to william dameshek, 1940-1950.

Michiels JJ, Institute And Foundation G, Education Thrombocythemia Vera Study Group FO, Ewg Mpn TA.

Turk J Haematol. 2013 Jun;30(2):102-10. doi: 10.4274/Tjh.2013.0029. Epub 2013 Jun 5. Review.

19.

Role of JAK-STAT signaling in the pathogenesis of myeloproliferative disorders.

Levine RL, Wernig G.

Hematology Am Soc Hematol Educ Program. 2006:233-9, 510. Review.

PMID:
17124066
20.

Supplemental Content

Support Center